ReviewPediatric research2026
Micro- and nanoplastics in pediatric health: from placental transfer to neurodevelopmental outcomes.
Review in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicro- and Nano plastic (MNP) contamination is an emerging environmental health concern with potential implications for pediatric health. Due to developmental susceptibility and higher relative exposure, fetuses, infants, and young children may be particularly vulnerable to MNP-related toxicity.
methodThis narrative review integrates evidence from animal models, human biomonitoring, and mechanistic studies to evaluate prenatal and early-life exposure pathways and potential neurodevelopmental consequences of MNPs. The synthesis addresses placental transfer, postnatal ingestion, inhalation, dermal exposure, and advances in analytical techniques for detection of biomarkers.
resultsHuman studies demonstrate the presence of microplastics in the placenta, amniotic fluid, cord blood, and feces, supporting transplacental and early-life exposure. Experimental evidence indicates that nanoplastics can cross biological barriers and may induce oxidative stress, inflammation, endocrine disruption, and altered neurotransmitter signaling. Animal studies consistently show structural and behavioral neurodevelopmental changes following early-life exposure. Emerging epidemiological data suggest associations between urinary microplastic markers and behavioral or cognitive outcomes in children, although causality remains unestablished.
conclusionCurrent evidence indicates that children are exposed to MNPs during critical developmental windows, with biologically plausible mechanisms linking exposure to adverse neurodevelopmental outcomes. Longitudinal human studies and child-specific dose-response data are urgently needed to inform risk assessment and guide public health strategies. IMPACT: Children represent a uniquely vulnerable population to microplastic and nanoplastic exposure, beginning with placental transfer and continuing through ingestion and inhalation in early life. Our findings highlight the urgent need for standardized detection methods for microplastic exposure and longitudinal studies in children linking exposure to neurodevelopmental outcomes. Protecting children from micro- and nanoplastic toxicity represents public health priority for future generations.
Identifiers
42811095What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.